Age-Related Cognitive Decline (ARCD) Support Protocol
Primary Stack
Core supplements with strongest evidenceAnti-inflammatory and neuroprotective; may improve memory and reduce brain amyloid accumulation
DHA is essential brain structural component; may slow cognitive decline and support memory
Supporting Stack
Additional supplements for enhanced resultsImproves cerebral blood flow and has antioxidant effects; may help with memory and processing speed
Supporting Studies (1)
Supports phospholipid synthesis and acetylcholine production; may improve memory and attention
Supporting Studies (1)
Major membrane phospholipid that supports cognitive function and may improve memory in elderly
Supporting Studies (1)
Deficiency associated with cognitive decline; supplementation may support brain health in elderly
Supporting Studies (1)
Reduce homocysteine which damages brain; B12 deficiency causes cognitive impairment
Traditional Ayurvedic herb that supports memory and cognitive function through multiple mechanisms
Supporting Studies (1)
Traditional Chinese herb that may enhance memory and protect neurons
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Age-related cognitive decline is the gradual decrease in mental abilities that occurs as we get older. This is different from dementia—it's the normal 'senior moments' many people experience: taking longer to learn new things, occasionally forgetting names, or feeling like your mind isn't as sharp as it used to be. While some cognitive decline is inevitable with aging, the rate and extent can be influenced by lifestyle factors and nutritional support.
IMPORTANT: Cognitive decline should be evaluated to distinguish normal aging from mild cognitive impairment (MCI) or early dementia. If you notice significant changes in memory or thinking, see a healthcare provider for proper assessment.
Expected timeline: Curcumin: 4-8 weeks. Omega-3: 8-12 weeks. Ginkgo: 4-8 weeks. B vitamins: 4-12 weeks. Bacopa: 8-12 weeks. Cognitive support is ongoing—these supplements work best with continued use.
Clinical Perspective
Age-associated cognitive decline encompasses the normal age-related changes in processing speed, working memory, and new learning while crystallized intelligence (vocabulary, general knowledge) is preserved. Mild Cognitive Impairment (MCI) represents a transitional state between normal aging and dementia with measurable deficits but preserved daily function. Pathophysiology involves synaptic loss, white matter changes, neuroinflammation, oxidative stress, vascular factors, and protein aggregation (tau, amyloid). Modifiable risk factors: cardiovascular disease, diabetes, depression, sleep apnea, hearing loss, social isolation.
CRITICAL: Cognitive complaints warrant medical evaluation to rule out treatable causes (B12 deficiency, thyroid, depression, sleep apnea, medications) and to assess for MCI/dementia. Supplements may support cognition but don't treat dementia. Lifestyle factors (exercise, social engagement, cognitive stimulation, cardiovascular risk management) have strong evidence.
Biomarker targets: Cognitive testing (MoCA, MMSE for screening; detailed neuropsychological testing if indicated), vitamin B12, homocysteine (<10 μmol/L), 25(OH)D (>40 ng/mL), thyroid function, basic metabolic panel, lipid profile, HbA1c.
Protocol notes: Physical exercise has strongest evidence for maintaining cognitive function—150 min/week moderate aerobic activity increases hippocampal volume and BDNF. Social engagement protects against decline. Cognitive stimulation (learning new skills, reading, puzzles) builds cognitive reserve. Mediterranean/MIND diet associated with lower dementia risk. Cardiovascular risk factor management critical—what's good for the heart is good for the brain. Treat sleep apnea (common, treatable cause of cognitive issues). Address hearing loss (associated with cognitive decline). Manage depression and anxiety. Moderate alcohol (or abstain). Avoid anticholinergic medications. Adequate sleep (7-8 hours). Stress management. Review medications that affect cognition. Regular cognitive screening in elderly. Distinguish normal aging from MCI from dementia for appropriate management.